Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.

© Shutterstock

Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible loss of vision.

The trial is being run by Nightstarx Ltd (Nightstar), a biopharmaceutical spinout company of Oxford developing gene therapies for inherited retinal diseases, and researchers from the University of Oxford led by NDCN's Professor Robert MacLaren.

On 16 March 2017, a 29 year old British man became the first patient with X-linked retinitis pigmentosa to undergo gene therapy. The operation took place at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Foundation Trust.

Read more.

Similar stories

Scientists uncover the role of neuronal networks in moving between wake and sleep states

Changes in the way that neurons communicate with each other affect our ability to move between sleep and wake states.

Professor Robert MacLaren receives Innovation Award

Professor Robert MacLaren is the winner of the Inspiring Leadership category in the Vice-Chancellor's Innovation Awards 2020 for his work on Nightstar, a retinal gene therapy company.

Seminar Summary: Interventions for improving chronic sleep disruption

DPhil student Lampros Bisdounis summarises a departmental seminar by Associate Professor Simon Kyle